Tevogen Bio's CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer's AI Discussion Panel

Core Insights - Tevogen Bio is leveraging AI to enhance precision medicine and operational efficiencies in the biotech sector [2][3] - The company is focused on developing off-the-shelf, genetically unmodified precision T cell therapies to address significant unmet medical needs [5][6] Company Overview - Tevogen Bio is a clinical-stage specialty immunotherapy company utilizing CD8+ cytotoxic T lymphocytes for treating infectious diseases and cancers [5] - The company has reported positive safety data from its proof-of-concept clinical trial and owns key intellectual property assets, including three granted patents and multiple pending patents related to AI [5][6] Industry Context - The AI discussion panel highlighted the transformative impact of AI across finance, biotech, and legal sectors, emphasizing the need for tailored approaches to address unique industry challenges [2][3] - The event featured industry leaders discussing the latest advancements in AI and its applications in enhancing operational efficiencies [4]